← Back to patent-cliff list
LTI-03
Tier C — Watch / tradeLTI-03
University Of Texas At Tyler
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：CAV1, MDM2
Indications (approved)：Idiopathic pulmonary fibrosis
Regional status
US
Phase II
2026-02-02
EU
Phase II
2026-02-02
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of LTI-03?
Approved indications include: Idiopathic pulmonary fibrosis.
When does the LTI-03 patent expire?
No public expiry year is available for LTI-03 yet; this page updates once verified.
How do I get a quote for LTI-03 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29